



ΚΥΠΡΙΑΚΗ ΔΗΜΟΚΡΑΤΙΑ
ΥΠΟΥΡΓΕΙΟ ΕΜΠΟΡΙΟΥ, ΒΙΟΜΗΧΑΝΙΑΣ ΚΑΙ ΤΟΥΡΙΣΜΟΥ



ΚΥΠΡΙΑΚΟ
ΕΜΠΟΡΙΚΟ ΚΑΙ
ΒΙΟΜΗΧΑΝΙΚΟ
ΕΠΙΜΕΛΗΤΗΡΙΟ



THE CYPRUS INSTITUTE OF
NEUROLOGY & GENETICS

Mass Media

9-5-2013

Press Release

Description Thread

Scientific Advancement by three Cypriot Scientists Hope for a new innovative treatment for Multiple Sclerosis

Dear Sir/Madam,

Our company, PALUPA Medical Ltd., is an incubator company (Helix Business Incubator) formed for the completion of a pioneer and innovative research program for the treatment of Multiple Sclerosis (MS) and continues its activities as a research and innovation company. The research project and clinical study was investigating the safety and therapeutic effect of a diet-drug formulation (nutraceutical) for this disease. The preparation has been designed entirely by a team of three Cypriot scientists (Dr. Patrikios I. Mr. Loukaides G. and Dr. Pantzaris M.) and produced in accordance with an innovative method of treatment philosophy and approach, the systems medicine, through systems biology. A holistic method that is for the first time ever applied towards the treatment of this chronic incurable disease.

Multiple sclerosis is a chronic multifactorial disease where the pathogenesis involves more than one factors (environmental, nutritional, genetic, etc.). It affects people in the most productive period of their lives (mostly between 18 and 45 years) and causes damage to the central nervous system, demyelination and degeneration of the nerve fibers. Existing treatments, available today, are limited primarily in terms of slowing the evolution of the disease, which in time leads to severe disability, without the possibility of complete cure. In contrast with our experimental intervention, all drugs currently available, even the ones that are to be approved for the treatment of the disease are made according to a different therapeutic approach and philosophy, the reductionism, and they are directed against a single pathogenic or pathogenetic process of the many that co-exist in the complex network of events leading to the disease.

All existing treatments today have a partial effect on the above specific complex network, often with serious side effects and with no chance of activation of the mechanisms involved in cellular protection, remyelination or regeneration. Such a multifactorial disease, however, cannot be addressed only with conventional methods in which medications can only be directed against a single agent or biological disorder from all the different Bio-pathological events that simultaneously coexist and interact, contributing to both the pathogenesis and the progression of the disease.



ΚΥΠΡΙΑΚΗ ΔΗΜΟΚΡΑΤΙΑ
ΥΠΟΥΡΓΕΙΟ ΕΜΠΟΡΙΟΥ, ΒΙΟΜΗΧΑΝΙΑΣ ΚΑΙ ΤΟΥΡΙΣΜΟΥ



ΚΥΠΡΙΑΚΟ
ΕΜΠΟΡΙΚΟ ΚΑΙ
ΒΙΟΜΗΧΑΝΙΚΟ
ΕΠΙΜΕΛΗΤΗΡΙΟ



THE CYPRUS INSTITUTE OF
NEUROLOGY & GENETICS

Specifically, existing treatments are based and focused on the effect against the result of a single factor among the many that are involved in the disease progression using a single micro-or macro-molecule. Interferons (first line treatment for multiple sclerosis) as the beta 1-a and beta 1-b and glatiramer acetate have fewer side effects but very low activity in the treatment of relapses or disability progression. The second-line drugs like Natalizumap (monoclonal antibody) and fingolimod (the only oral drug -all other drugs are injectable either subcutaneously / intramuscularly or intravenously) have better effect on disease progression and slowdown of the evolutionary course of the disease, but both are associated with serious side effects even fatal complications. Even the drugs that are about to be added to the therapeutic armamentarium of physicians, in the near future (some have already been approved in the USA and are awaiting approval in Europe), are either the same or partially effective but again are all associated with serious side effects. Recent studies on the quality of life of MS patients have shown that most patients are tired and frustrated after all treatments; they have severe side effects and because of their obligation to either undergo regular injections or entering hospitals for their administration. The change in the quality of their lives begins immediately after the first administration of conventional injecting drugs. No other treatment is available in the market other than the above.

Understandably all pharmaceutical companies are in a race exploring possible alternative medication or new generation drugs, based on innovative holistic treatment approaches.

The study was performed from July 2007 until December 2010, according to the global standards of clinical research for the disease and with the participation of 80 patients with relapsing multiple sclerosis. The study design and the medical protocol included many innovations leading to the preparation of the formulation. Unlike anything else available, this formulation (with the code PLP10) is a nutraceutical (with natural biomolecules), administered orally, can be co-administered with all other available treatments, showed great therapeutic effect in reducing the frequency of relapses (flares) of the disease but mainly on the progression of the disability of patients. Finally, it is also potentially able to trigger remyelination, neuroprotection and mainly free of side effects. It thus has the ability to influence a holistic treatment of the disease, since it can affect the total known biological and biochemical network of pathogenic / pathogenetic events and mechanisms that cause the disease, including the biochemical mechanisms responsible for remyelination and restoration of neurons (healing).

Upon completion of our clinical study and research, we are pleased to be able to announce the of-international interest intriguing research results for the treatment of the disease in relation to the PLP10 preparation.

The study was accepted and published a few days ago in one of the most prestigious and world-class medical scientific literature, the British Medical Journal, in the open edition, after an independent assessment by world-class scientists with knowledge, long-term experience and international recognition in research and treatment of MS. The product is registered for a USA and a worldwide patent.



ΚΥΠΡΙΑΚΗ ΔΗΜΟΚΡΑΤΙΑ
ΥΠΟΥΡΓΕΙΟ ΕΜΠΟΡΙΟΥ, ΒΙΟΜΗΧΑΝΙΑΣ ΚΑΙ ΤΟΥΡΙΣΜΟΥ



ΚΥΠΡΙΑΚΟ
ΕΜΠΟΡΙΚΟ ΚΑΙ
ΒΙΟΜΗΧΑΝΙΚΟ
ΕΠΙΜΕΛΗΤΗΡΙΟ



THE CYPRUS INSTITUTE OF
NEUROLOGY & GENETICS

The results are receiving huge interest from the global scientific and medical community. The published report from the study-results is independently mounted as a major-point issue to over 300 authoritative electronic pages, first issue to national Multiple Sclerosis Organizations websites (including America, UK and Australia), it is recognized as the most highlighted research of the week for three consecutive weeks by the British Multiple Sclerosis Trust, it is posted in many discussions web-pages of scientific interest, it is the first theme in the pages of new treatments and since the day of publication it is in the list of the most widely read scientific journals with reports through television stations worldwide. According to Almetric, a Statistical Office of published scientific literature worldwide, our publication, among 1,300,000 scientific publications in all scientific journals and media (8,122), it's **in the top 5% of all articles ever tracked** by Almetric.

In more detail, compared to the other treatments, our formulation by the code PLP10, versus placebo showed significant healing abilities for the sample of patients in the study, reducing the frequency of relapses of the disease up to 72% and the possibility of disability progression up to 86% without any severe side effects and with potential of recovery (remyelination) and neuro-cell protection. All this in contrast with the conventional methods wherein: interferons and glatiramer acetate reduce the frequency of relapses only by about a third, without significant effect on progression of disability, Natalizumab with 68% reduction in the frequency of relapses and a 43% reduction of the probability of increasing disability and fingolimod with 54% reduction in the frequency of relapses without significant effect on the evolution of the degree of disability in relation to interferons and Copaxone. Additionally, all of the above drugs have not demonstrated any significant cytoprotection or restorative abilities and are associated with severe side effects even fatal.

Regarding the economic benefits will be huge for both our company as well as for Cyprus since there are more than 3,000,000 patients worldwide and with multiple sclerosis population to double approximately every 10-12 years. But it is important and scientific advancement of such pioneering formulations and holistic type of therapies, as they open a new era and new horizons in the treatment of chronic diseases that never before received testing and implementation, aiming to improve the quality of life of patients. In America alone, approximately 500,000 patients are suffering from MS. According to the American National Association of MS the financial cost of caring for these patients, including medical and non-medical care as well as production losses are exceeding \$ 23 billion annually, or more than \$ 57,000 per patient. Due to the nature of the new formulation (nutraceutical) it will be significantly cheaper than the existing MS drugs in the market and it will contribute significantly to the local and global socio-economic progress in a period of prolonged global economic downturn.

The clinical study was conducted by our company at the Institute of Neurology and Genetics with almost exclusive economic sponsorship by the Ministry of Commerce, Industry and Tourism of Cyprus and with partial subsidy of the raw materials from Yasoo Health Co.

The website of the published literature is: <http://bmjopen.bmj.com/content/3/4/e002170.full>

The promotion and communication of the results of the study is considered necessary as the type of formulation and the positively pioneer results itself trigger enormous interest, making us responsible with the obligation to disseminate them, mostly via the media to inform both, patients and scientists. The formulation itself, as well as the new therapeutic approach to the disease through holistic medicine and medical systems, is a formidable light-beam for persons suffering with this incurable chronic disease and not only. Additionally, there are several scientific evidence for use of the formulation for other neurodegenerative diseases such as Parkinson's, Alzheimer's etc. Finally, the profile and safety of the intervention/formulation PLP10 makes it engaging enough for even the prevention of MS in patients with Clinically Isolated Syndrome (CIS), ie with the first stroke of MS or even for chronic neurodegenerative diseases such as Alzheimer's disease, the greatest scourge of mankind today.

The registered partners and involved researchers are all Cypriot scientists: Dr. Ioannis Patrikios, Professor of Medical Biochemistry, Associate Senior Researcher at the Institute of Neurology and Genetics and Visiting Professor at the European University of Cyprus; Mr George Loukaides, certified nutritionist / dietician, a PhD candidate and associate at the Institute of Neurology and Genetics and Dr. Marios Pantzaris, Senior Neurologist, Director of the Third Neurology and Multiple Sclerosis Clinic at the Institute of Neurology and Genetics.

Today we are also able to announce the start of the last stage of formulation development, that is considered necessary by the organizations for new therapeutic agents before placing them in the markets; probably again with a financial grant from the Ministry of Commerce, Industry and Tourism of Cyprus, after our proposal, for a new study, has been accepted as eligible for funding. This phase III multicenter study, will engage a larger patient population from the Institute of Neurology and Genetics in collaboration with three university medical centers in Greece (Aristotle University of Thessaloniki, University of Thessaly and University of Ioannina). Other cooperation centers for carrying out the study are located in Great Britain (University of Southampton) and Italy (University Vita-Salute San Raffaele in Milan).

Finally, the team wishes to thank all the patients participating in the study, all of the parties involved in the study, like all the nurses in the ward, the outpatient nurse Eftihia Ganglia and the pharmacist Elena Kkolou from the Institute of Neurology and Genetics of Cyprus, the Ayios Therissos medical diagnostic center, the Helix Business Incubator and especially Mr Hatzisofokli Dimitris and Joanna Leontiou, the Institute of Neurology and Genetics for the whole cooperation and hospitality, the company Yasoo Health Ltd for the partial supply of raw materials, CCCI for donating the room space and the full cooperation for the success of today's conference, and finally, the main financier of the project and co-organizer of today's major event, the Ministry of Commerce, Industry and Tourism of Cyprus.

For more information please contact us.



ΚΥΠΡΙΑΚΗ ΔΗΜΟΚΡΑΤΙΑ
ΥΠΟΥΡΓΕΙΟ ΕΜΠΟΡΙΟΥ, ΒΙΟΜΗΧΑΝΙΑΣ ΚΑΙ ΤΟΥΡΙΣΜΟΥ



ΚΥΠΡΙΑΚΟ
ΕΜΠΟΡΙΚΟ ΚΑΙ
ΒΙΟΜΗΧΑΝΙΚΟ
ΕΠΙΜΕΛΗΤΗΡΙΟ



THE CYPRUS INSTITUTE OF
NEUROLOGY & GENETICS

The contact email address is: patrikiosioannis@gmail.com

Telephone: +357 99097856 (Prof. Dr. John Patrick, a company PALUPA med.)

Regards
Prof. Dr. Ioannis Patrikios
George Loucaides,
Dr. Marios Pantzaris

PaLuPa
Medical